Fate Therapeutics INC Form 4 insider transactions

A director at Fate Therapeutics, Neelufar Mozaffarian, was granted 55,000 stock options with an exercise price of $1.32, as part of the company's non-employee director compensation policy.

William H. Rastetter, a Director at Fate Therapeutics Inc., was granted 55,000 stock options with an exercise price of $1.32, vesting in 2026.

John Mendlein, a Director at Fate Therapeutics Inc., was granted 55,000 stock options with an exercise price of $1.32 per share, as part of the company's non-employee director compensation policy.

Fate Therapeutics, Inc. Director Karin Jooss was granted 55,000 stock options with an exercise price of $1.32, vesting on May 29, 2026, or the 2026 Annual Meeting, as part of the company's non-employee director compensation policy.

Fate Therapeutics, Inc. Director Robert S. Epstein was granted 55,000 stock options at an exercise price of $1.32 per share, vesting over one year, as part of the company's non-employee director compensation policy.

Fate Therapeutics Inc. Director Matt Abernethy was granted 110,000 stock options with an exercise price of $1.32, vesting over three years.

Fate Therapeutics' CEO, Bahram Valamehr, was granted 1.3 million stock options with a vesting schedule over three years.

Cindy Tahl, Chief Legal & Compliance Officer and Secretary at Fate Therapeutics, acquired 70,000 shares of common stock and 275,000 stock options on January 15, 2025.

Fate Therapeutics' Chief Regulatory and Quality Officer, Jerome Charles Bressi, was granted stock options and restricted stock units on January 15, 2025.

Jerome Charles Bressi, Chief Regulatory and Quality Officer of Fate Therapeutics, sold shares to cover tax withholding obligations related to vesting RSUs.

Cindy Tahl, Chief Legal & Compliance Officer and Secretary of Fate Therapeutics, sold shares to cover tax withholding obligations related to vesting RSUs.

Fate Therapeutics CEO, Bahram Valamehr, sold 8,705 shares of common stock to cover tax obligations related to vesting restricted stock units.

Redmile Group, a significant shareholder in Fate Therapeutics, engaged in cross trades of common and preferred stock, maintaining its substantial beneficial ownership while also closing out a portion of cash-settled swap agreements.

Redmile Group, a significant shareholder in Fate Therapeutics, converted preferred stock to common stock and adjusted its reported holdings due to a change in investment advisory roles.

Director Yuan Xu of Fate Therapeutics sold 633 shares of common stock at a price of $4.23 per share on August 6, 2024, under a pre-arranged 10b5-1 trading plan.

Bahram Valamehr, Chief R&D Officer of Fate Therapeutics, was granted 200,000 shares of common stock through a restricted stock unit award with both time-based and performance-based vesting conditions.

Director Neelufar Mozaffarian of Fate Therapeutics received stock options exercisable for 80,000 shares of common stock.

Cindy Tahl, General Counsel and Secretary of Fate Therapeutics, was granted 200,000 shares of common stock through restricted stock units with both time-based and performance-based vesting conditions.

Michael Lee, a director of Fate Therapeutics, was granted stock options for 40,000 shares in connection with his board service.

Redmile Group, LLC, a significant shareholder in Fate Therapeutics Inc., reports the acquisition of a stock option grant through its managing director's board service.

Director William H Rastetter of Fate Therapeutics received stock options for 40,000 shares on June 7, 2024, as part of the company's non-employee director compensation policy.

Director Karin Jooss received stock options for 40,000 shares of Fate Therapeutics (FATE) on June 7, 2024, as part of the company's non-employee director compensation policy.

Director Timothy Coughlin received a grant of stock options from Fate Therapeutics on June 7, 2024, according to a Form 4 filing.

Director Shefali Agarwal received stock options for 40,000 shares of Fate Therapeutics common stock on June 7, 2024, as part of the company's non-employee director compensation policy.

Director Yuan Xu of Fate Therapeutics was granted 40,000 stock options on June 7, 2024, according to a Form 4 filing with the SEC.

Director Robert Epstein received 40,000 stock options in Fate Therapeutics (FATE) on June 7, 2024, as part of the company's non-employee director compensation policy.

Director John Mendlein received a stock option grant from Fate Therapeutics on June 7, 2024, according to a Form 4 filing.

Redmile Group, through managed investment vehicles, acquired pre-funded warrants to purchase 3,636,364 shares of Fate Therapeutics common stock in a private placement concurrent with a public offering.

Edward J. Dulac III, CFO of Fate Therapeutics, sold 2,447 shares of common stock at $7.77 per share on March 4, 2024, under a pre-arranged Rule 10b5-1 trading plan.